glp-1 colorectal cancer death risk study november 2025 Association between receptor agonists as a class and risk: a meta-analysis of retrospective cohort studies | BMC Gastroenterology glp-1 colorectal cancer mortality study

Non-alcoholic fatty liver disease in morbidly obese individuals undergoing bariatric surgery: prevalence and effect of the pre-bariatric very low calorie diet

Systemic effects like headache occur in approximately 1015% of patients but typically resolve within the first month of therapy

The results of this rodent study showed superior glycemic control effects compared to cotadutide and liraglutide with greater weight loss compared to liraglutide, but similar to the cotadutide [70]

Your health and safety come first

Pharmacy benefit managers (PBMs) contracted with Cigna occasionally impose quantity limits or refill restrictions, capping monthly injections even if your physician determines higher doses are medically necessary

Alongside Mounjaro and Saxenda, its one of three GLP-1 drugs prescribed by the NHS specifically for weight loss (whereas Ozempic which uses the same active ingredient as Wegovy is only approved for the treatment of type 2 diabetes) and is also available to purchase privately through specialist pharmacies